These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31779848)

  • 1. Challenges in systemic sclerosis trial design.
    Denton CP
    Semin Arthritis Rheum; 2019 Dec; 49(3S):S3-S7. PubMed ID: 31779848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS).
    Zheng B; Hudson M; Wang M; Baron M;
    Arthritis Res Ther; 2020 Jun; 22(1):132. PubMed ID: 32503616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis.
    Khanna D; Huang S; Lin CJF; Spino C
    Ann Rheum Dis; 2021 May; 80(5):641-650. PubMed ID: 33257497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.
    White B; Bauer EA; Goldsmith LA; Hochberg MC; Katz LM; Korn JH; Lachenbruch PA; LeRoy EC; Mitrane MP; Paulus HE
    Arthritis Rheum; 1995 Mar; 38(3):351-60. PubMed ID: 7880189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).
    Khanna D; Distler O; Avouac J; Behrens F; Clements PJ; Denton C; Foeldvari I; Giannini E; Huscher D; Kowal-Bielecka O; Lovell D; Matucci-Cerinic M; Mayes M; Merkel PA; Nash P; Opitz CF; Pittrow D; Rubin L; Seibold JR; Steen V; Strand CV; Tugwell PS; Varga J; Zink A; Furst DE; ;
    J Rheumatol; 2009 Oct; 36(10):2356-61. PubMed ID: 19820225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.
    Domsic RT; Medsger TA; Gao S; Laffoon M; Huang S; Wisniewski S; Spino C; Steen V; Lafyatis R; Khanna D
    Rheumatology (Oxford); 2023 Apr; 62(4):1543-1551. PubMed ID: 36031807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study.
    Park EH; Strand V; Oh YJ; Song YW; Lee EB
    Arthritis Res Ther; 2019 Feb; 21(1):61. PubMed ID: 30770765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs in phase I and phase II clinical trials for systemic sclerosis.
    Chung MP; Chung L
    Expert Opin Investig Drugs; 2020 Apr; 29(4):349-362. PubMed ID: 32178544
    [No Abstract]   [Full Text] [Related]  

  • 10. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
    Khanna D; Furst DE; Clements PJ; Park GS; Hays RD; Yoon J; Korn JH; Merkel PA; Rothfield N; Wigley FM; Moreland LW; Silver R; Steen VD; Weisman M; Mayes MD; Collier DH; Medsger TA; Seibold JR; ;
    J Rheumatol; 2005 May; 32(5):832-40. PubMed ID: 15868618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of skin involvement in systemic sclerosis.
    Kumánovics G; Péntek M; Bae S; Opris D; Khanna D; Furst DE; Czirják L
    Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v53-v66. PubMed ID: 28992173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.
    Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Seibold JR
    Arthritis Rheum; 2001 Mar; 44(3):653-61. PubMed ID: 11263780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin fibrosis correlates with circulating thyrotropin levels in systemic sclerosis: translational association with Hashimoto's thyroiditis.
    Bagnato GL; Roberts WN; Fiorenza A; Arcuri C; Certo R; Trimarchi F; Ruggeri RM; Bagnato GF
    Endocrine; 2016 Feb; 51(2):291-7. PubMed ID: 25994300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthy children have a significantly increased skin score assessed with the modified Rodnan skin score.
    Foeldvari I; Wierk A
    Rheumatology (Oxford); 2006 Jan; 45(1):76-8. PubMed ID: 16174648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
    Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
    Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.
    Wannarong T; Muangchan C
    Rheumatol Int; 2018 Dec; 38(12):2279-2288. PubMed ID: 30206672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-frequency ultrasound of the skin in systemic sclerosis: an exploratory study to examine correlation with disease activity and to define the minimally detectable difference.
    Li H; Furst DE; Jin H; Sun C; Wang X; Yang L; He J; Wang Y; Liu A
    Arthritis Res Ther; 2018 Aug; 20(1):181. PubMed ID: 30115105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma.
    Johnson SR; Feldman BM; Pope JE; Tomlinson GA
    J Rheumatol; 2009 Feb; 36(2):323-9. PubMed ID: 19040308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
    Khanna D; Seibold J; Goldin J; Tashkin DP; Furst DE; Wells A
    Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v27-v32. PubMed ID: 28992174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of right ventricular myocardial function with skin and pulmonary involvement in asymptomatic patients with systemic sclerosis.
    D'Andrea A; Bellissimo S; Scotto di Uccio F; Vigorito F; Moscato F; Tozzi N; Di Donato M; Citro R; Stisi S; Scherillo M
    Ital Heart J; 2004 Nov; 5(11):831-9. PubMed ID: 15633438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.